<DOC>
	<DOCNO>NCT00452478</DOCNO>
	<brief_summary>The main aim research study see give Fosrenol® , chewable tablet , patient haemodialysis work well treatment currently use low blood phosphorus level .</brief_summary>
	<brief_title>Conversion From Standard Phosphate Binder Therapy Fosrenol® ( Lanthanum Carbonate ) Chronic Kidney Disease Stage 5</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Male female subject great equal 18 year age receive stable regimen haemodialysis chronic kidney disease ( CKD ) Stage 5 ( define haemodialysis two three time per week least two month prior screen ) . Females child bear potential ( FOCP ) must nonpregnant , nonlactating , negative serum beta human chorionic gonadotropin ( HCG ) test , agree comply applicable contraceptive requirement protocol . Subjects stable phosphate binder dose ( defined change medication dosage least one month prior screen ) serum phosphorus level great 1.78 less equal 2.43 mmol/L ( 5.5 7.5 mg/dL ) . Subjects correct serum calcium level le 2.1 mmol/L ( 8.5 mg/dL ) . Subjects intact parathyroid hormone ( iPTH ) level great 500 pg/mL , history previous parathyroidectomy within 12 month screen . Subjects significant bowel obstruction , active inflammatory bowel disease , gastrointestinal ( GI ) motility disorder , abnormal irregular bowel motion , history major GI surgery within last 6 month exclude . Subjects receive aluminium , magnesium , combination therapy sevelamer hydrogen chloride ( HCl ) calcium phosphate binder time screen exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Hyperphosphataemia</keyword>
</DOC>